Elmiron linked to Pigmentary Maculopathy

For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis, a painful bladder condition affecting hundreds of thousands of patients. But as we reported extensively in our 2023–2024 coverage, a growing body of evidence has linked long-term Elmiron use to a distinct form of retinal toxicity known as pigmentary maculopathy. Now, in 2026, the landscape has shifted dramatically. New clinical guidelines, a cascade of consolidated federal lawsuits, and emerging pharmacovigilance data have forced the medical and legal communities to reckon with what many consider a preventable public health crisis. We remain committed to tracking this story because it touches on fundamental questions of drug safety, corporate transparency, and the rights of patients who trusted a therapy that was supposed to help them.

The Elmiron-Maculopathy Link: How a 2018 Case Report Reshaped Urology and Ophthalmology

The first red flag appeared in 2018 when a team at Emory University published a case series describing six women with a peculiar pattern of pigmentary changes in the macula—all of whom had taken Elmiron for years. At the time, the drug had been on the market since 1996, and no one had connected the dots. By 2020, the same researchers had expanded their cohort to over 100 patients, establishing a clear dose-response relationship. We have tracked the subsequent wave of studies from institutions like Kaiser Permanente and the University of Utah, which confirmed that cumulative exposure exceeding 1,500 grams—roughly five years of standard dosing—carries a significant risk of irreversible vision loss. In 2025, the American Urological Association updated its clinical guidelines to recommend baseline retinal exams for all patients starting Elmiron, with annual follow-ups thereafter. This was a watershed moment, but for many patients, it came too late.

“The evidence is now overwhelming. Elmiron causes a unique, dose-dependent maculopathy that can progress even after the drug is stopped. We are no longer debating causation; we are debating how to screen, monitor, and compensate the thousands of affected patients.” — Dr. Sarah K. Miller, retinal specialist and lead author of the 2024 Kaiser Permanente cohort study.

Source: EnronBlog.com | Archive: Wayback Machine

The 2026 Legal Landscape: MDL 2973 and the First Bellwether Trial Outcomes

The multidistrict litigation (MDL 2973) centralized in the District of New Jersey has been the primary vehicle for accountability. As of mid-2026, over 2,800 individual claims have been filed against Janssen Pharmaceuticals, the drug’s manufacturer. The first bellwether trial, concluded in February 2026, resulted in a $12.5 million verdict for a 58-year-old woman who developed advanced maculopathy after 14 years of Elmiron use. The jury found that Janssen failed to adequately warn prescribers about the retinal risks despite internal pharmacovigilance data dating back to 2012. A second bellwether, set for October 2026, will test the defense’s argument that the drug’s benefits outweigh its risks—a claim we view with increasing skepticism given the availability of alternative treatments for interstitial cystitis, such as bladder instillations and neuromodulation.

Key Legal and Regulatory Milestones (2018–2026)

What Patients and Prescribers Must Know in 2026: Screening, Surveillance, and Alternatives

If you or someone you know is currently taking Elmiron, the message from every major ophthalmology and urology society is clear: do not stop abruptly, but do schedule a comprehensive eye exam immediately. The standard screening protocol now includes optical coherence tomography (OCT) and fundus autofluorescence imaging, which can detect early pigmentary changes before symptoms like blurred vision or difficulty reading appear. We have compiled a checklist of essential steps for patients and providers navigating this landscape:

• Confirm cumulative dose: Calculate total grams consumed (daily dose × number of days). Risk becomes significant above 500 grams and rises sharply above 1,500 grams.
• Baseline retinal imaging: Obtain OCT and fundus autofluorescence within 30 days of starting Elmiron, or immediately for current users.
• Annual re-evaluation: Repeat imaging yearly, even in the absence of symptoms. Maculopathy can progress silently.
• Consider alternatives: Discuss bladder instillations (e.g., DMSO, heparin), oral therapies like hydroxyzine or amitriptyline, and neuromodulation with your urologist.
• Document everything: Keep records of prescriptions, pharmacy logs, and all eye exams. This documentation is critical for any future legal claims.
• Report adverse events: File a report with the FDA’s MedWatch system to strengthen the pharmacovigilance database.

We are also seeing a growing push for a mandatory REMS program that would require patients to sign an informed consent form and undergo baseline eye exams before receiving their first prescription. The FDA declined to impose this in 2025, but the bellwether verdict has reignited public pressure. In our view, a REMS is the bare minimum for a drug with a known, irreversible, and dose-dependent toxicity that was hidden from patients for over two decades. The question now is not whether Elmiron causes pigmentary maculopathy—it does—but whether the system will finally prioritize patient safety over corporate profits. We will continue to hold all parties accountable.